Lovotibeglogene autotemcel (Lyfgenia)
Gene therapy / editing
Evidence outlook
Approved: Sickle Cell Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04293185 NCT04293185 · Sickle Cell Disease Registry: NCT04293185 | 3 | VOE-CR (6-18 months post-transplant) 2027-05 | In progress: results expected 1 May 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Sickle Cell Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Lovotibeglogene Autotemcel (Lyfgenia): this drug | Approved | Gene therapy / editing | Beta-globin gene addition (betaA-T87Q) | not yet graded | No reviewed efficacy summary in this indication | |
| Crizanlizumab-Tmca (Adakveo) | Approved | Monoclonal antibody | P-selectin | Partial signal | Featured results are non-efficacy only in this race | |
| Exagamglogene Autotemcel (Casgevy) | Approved | Gene therapy / editing | BCL11A erythroid enhancer (gene editing) | Weak signal | No reviewed efficacy summary in this indication | |
| Hydroxyurea (Droxia) | Approved | Small molecule | Ribonucleotide reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Hydroxyurea (Siklos) | Approved | Small molecule | Ribonucleotide reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Hydroxyurea (Xromi) | Approved | Small molecule | Ribonucleotide reductase | Weak signal | No reviewed efficacy summary in this indication | |
| L-Glutamine (Endari) | Approved | Small molecule | Amino Acid | Reliable signal | NCT01179217: The Number of Occurrences of Sickle Cell Crises (48 weeks): L-glutamine 3 Number of crises (range 0 to 15) | 100% Maltodextrin 4 Number of crises (range 0 to 15) | |
| Etavopivat | Phase 3 | — | Pyruvate kinase | not yet graded | No reviewed efficacy summary in this indication | |
| Mitapivat (Pyrukynd) | Phase 3 | Small molecule | Pyruvate kinase | not yet graded | No reviewed efficacy summary in this indication | |
| Decitabine / Tetrahydrouridine (NDec) | Phase 2 | Small molecule | DNMT1 (DNA methyltransferase 1) | not yet graded | No reviewed efficacy summary in this indication | |
| HBI-002 | Phase 2 | Small molecule | Carbon monoxide (CO)-based gas therapeutic; oral liquid CO formulation | not yet graded | No reviewed efficacy summary in this indication | |
| ITU512 | Phase 1/2 | Small molecule | WIZ transcription factor | not yet graded | No reviewed efficacy summary in this indication | |
| Nula-Cel | Phase 1/2 | Gene or cell therapy (subtype unspecified) | HBB gene (sickle mutation correction) | not yet graded | No reviewed efficacy summary in this indication | |
| Ristoglogene Autogetemcel | Phase 1/2 | Gene therapy / editing | HBG1/HBG2 promoters | not yet graded | No reviewed efficacy summary in this indication | |
| DISC-3405 | Phase 1 | Monoclonal antibody | TMPRSS6 (matriptase-2) | not yet graded | No reviewed efficacy summary in this indication | |
| SCD-101 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| VAS-101 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Iloprost (Ventavis) | Discontinued | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Renizgamglogene Autogedtemcel | Discontinued | Gene or cell therapy (subtype unspecified) | HBG1/HBG2 promoters | not yet graded | No reviewed efficacy summary in this indication | |
| Voxelotor (Oxbryta) | Discontinued | Small molecule | Hemoglobin S (HbS) | Reliable signal | NCT03036813: Haemoglobin response (>1 g/dL rise at week 24): voxelotor 1500 mg 46/90, 900 mg 30/92, placebo 6/92 |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Lovotibeglogene autotemcel (Lyfgenia) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.